AgeX Therapeutics, Inc. (AGE)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.6610 |
| Open | 0.6300 |
| Bid | 0.6270 x 900 |
| Ask | 0.6941 x 1100 |
| Day's Range | 0.6300 - 0.6630 |
| 52 Week Range | 0.5000 - 1.1200 |
| Volume | |
| Avg. Volume | 18,285 |
| Market Cap | 25.159M |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2880 |
| Earnings Date | May 15, 2023 - May 19, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
ALAMEDA, Calif., March 31, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.
- Business Wire
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
ALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio
- Business Wire
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
ALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022.
